ViroPharma Incorporated – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 31 PAGES: 80

More Info
									[




    ViroPharma Incorporated – Product Pipeline Review – 2012

                                                                                          Reference Code: GMDHC02244CDB
                                                                                                 Publication Date: MAY 2012




ViroPharma Incorporated – Product Pipeline Review – 2012                                  GMDHC02244CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
ViroPharma Incorporated – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 6
ViroPharma Incorporated Snapshot ................................................................................................................................................... 7
    ViroPharma Incorporated Overview............................................................................................................................................... 7
    Key Information ............................................................................................................................................................................. 7
    Key Facts....................................................................................................................................................................................... 7
ViroPharma Incorporated – Research and Development Overview ................................................................................................... 8
    Key Therapeutic Areas .................................................................................................................................................................. 8
ViroPharma Incorporated – Pipeline Review .................................................................................................................................... 10
    Pipeline Products by Stage of Development ............................................................................................................................... 10
    Pipeline Products – Monotherapy ............................................................................................................................................... 11
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 12
ViroPharma Incorporated – Pipeline Products Glance ..................................................................................................................... 13
    ViroPharma Incorporated – Late Stage Pipeline.......................................................................................................................... 13
        Registration Filed Products/Combination Treatment Modalities.............................................................................................. 13
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 14
    ViroPharma Incorporated Clinical Stage Pipeline Products ......................................................................................................... 15
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 15
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 16
    ViroPharma Incorporated – Early Stage Pipeline Products ......................................................................................................... 17
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 17
ViroPharma Incorporated – Drug Profiles ......................................................................................................................................... 18
    Cinryze ........................................................................................................................................................................................ 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    Cinryze + rHuPH20...................................................................................................................................................................... 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
    VP 20621 ..................................................................................................................................................................................... 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    VP-20629 .................................................................................................................................................................................... 24
        Product Description................................................................................................................................................................. 24
        Mechanism of Action ............................................................................................................................................................... 24
        R&D Progress ......................................................................................................................................................................... 24
ViroPharma Incorporated – Pipeline Analysis .................................................................................................................................. 26
    ViroPharma Incorporated – Pipeline Products by Therapeutic Class .......................................................................................... 26
    ViroPharma Incorporated – Pipeline Products By Target ............................................................................................................ 27



ViroPharma Incorporated – Product Pipeline Review – 2012                                                                                GMDHC02244CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
ViroPharma Incorporated – Product Pipeline Review



    ViroPharma Incorporated – Pipeline Products by Route of Administration .................................................................................. 28
    ViroPharma Incorporated – Pipeline Products By Mechanism of Action ..................................................................................... 29
ViroPharma Incorporated – Recent Pipeline Updates ..................................................................................................................... 30
ViroPharma Incorporated - Dormant Projects................................................................................................................................... 33
ViroPharma Incorporated - Discontinued Pipeline Products ............................................................................................................. 34
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 34
        Camvia .................................................................................................................................................................................... 34
        HCV-796 ................................................................................................................................................................................. 34
        HCV-796 + Peg-Intron + Rebetol ............................................................................................................................................ 34
Angelini Group – Company Statement ............................................................................................................................................. 35
Angelini Group – Locations And Subsidiaries................................................................................................................................... 38
    Head Office.................................................................................................................................................................................. 38
    Other Locations & Subsidiaries ................................................................................................................................................... 38
Angelini Group, Recent Developments ............................................................................................................................................ 40
    Angelini Group- Press Release ................................................................................................................................................... 40
        Apr 11, 2012: Prasco To Launch Generic Version Of Vancocin HCl Capsules ...................................................................... 40
        Apr 10, 2012: ViroPharma Provides Update On Status Of Citizen Petition Regarding Bioequivalence And Exclusivity For
        Vancocin Capsules ................................................................................................................................................................. 40
        Mar 06, 2012: ViroPharma And Halozyme Report Positive Phase II Trial Data Of Subcutaneous Cinryze With rHuPH20 .... 41
        Feb 29, 2012: ViroPharma's Cinryze Available In UK For Routine Prevention Of Hereditary Angioedema Attacks ............... 43
        Feb 07, 2012: ViroPharma Provides Update On Industrial Scale Supplement For Cinryze .................................................... 44
        Jan 13, 2012: Health Canada Grants Priority Review Status For New Drug Submission For ViroPharma's Cinryze ............. 45
        Jun 04, 2009: ViroPharma Receives Complete Response Letter for Cinryze Supplemental Biologics License Application for
        Acute Treatment of Hereditary Angioedema ........................................................................................................................... 46
        May 26, 2009: Scientific Data Relating to Cinryze Presented at 6th Annual C1 Inhibitor Deficiency Workshop ..................... 46
        Mar 18, 2009: ViroPharma Submits Comments on Vancocin Draft Bioequivalence Guidance ............................................... 47
        Mar 03, 2009: Intellect Neurosciences, Inc. Announces Independent Studies On Copper Binding Properties Of Its Lead
        Candidate OXIGON ................................................................................................................................................................ 47
        Feb 03, 2009: FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze C1 Inhibitor (Human)
        as Treatment for Acute Attacks of Hereditary Angioedema (HAE).......................................................................................... 48
Financial Deals Landscape .............................................................................................................................................................. 49
    ViroPharma Incorporated, Deals Summary ................................................................................................................................. 49
ViroPharma Incorporated, Pharmaceuticals & Healthcare, Deal Details .......................................................................................... 51
    Asset Transactions ...................................................................................................................................................................... 51
        ViroPharma Acquires Vancocin Brand From Eli Lilly .............................................................................................................. 51
    Partnerships ................................................................................................................................................................................ 53
        ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin ............................................................... 53
    Licensing Agreements ................................................................................................................................................................. 54
        ViroPharma Enters Into Licensing Agreement With Intellect Neurosciences For OX1............................................................ 54
        ViroPharma Enters Into Licensing Agreement With Halozyme Therapeutics.......................................................................... 56
        ViroPharma Expands Licensing Agreement With Sanquin Blood Supply Foundation ............................................................ 58
        ViroPharma Enters Into Licensing Agreement With Dr. Dale N. Gerding................................................................................ 60
        ViroPharma Enters Into Licensing Agreement With Schering-Plough..................................................................................... 61
    Equity Offering ............................................................................................................................................................................. 63
        ViroPharma Completes Public Offering Of $173.36 Million ..................................................................................................... 63



ViroPharma Incorporated – Product Pipeline Review – 2012                                                                                GMDHC02244CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                      Page(3)
ViroPharma Incorporated – Product Pipeline Review



    Debt Offering ............................................................................................................................................................................... 65
         ViroPharma Completes Public Offering Of Convertible Notes For $250 Million ...................................................................... 65
         ViroPharma Completes Private Placement Of Convertible Notes For $75 Million .................................................................. 67
    Asset Transactions ...................................................................................................................................................................... 68
         MicroDose Therapeutx Acquires Investigational Compounds From ViroPharma.................................................................... 68
         ViroPharma Sells Biodefense Assets To SIGA Technologies ................................................................................................. 70
    Acquisition ................................................................................................................................................................................... 72
         ViroPharma Enters Into Option To Acquire Meritage Pharma................................................................................................. 72
         ViroPharma Acquires DuoCort Pharma For $165 Million ........................................................................................................ 74
         ViroPharma Acquires Auralis ........................................................................
								
To top